Study on the Priorities of Patients Admitted to Intensive Care (PRIOREA)

March 3, 2026 updated by: University Hospital, Brest
The goal of this observational study is to learn about the priorities of patients admitted to intensive care units (ICUs) who have a life-threatening condition, as well as the priorities assumed by their designated relatives and healthcare professionals (nurses, nursing assistants, ICU physicians, and general practitioners).

Study Overview

Status

Not yet recruiting

Conditions

Study Type

Observational

Enrollment (Estimated)

100

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

  • France
      • Brest, France, 29200
        • CHU de Brest
        • Contact:
        • Principal Investigator:
          • Thomas GARGADENNEC, MD

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Sampling Method

Non-Probability Sample

Study Population

Patient admitted to intensive care Contact person for patients admitted to intensive care Caregiver for patients admitted to intensive care Family doctor for patients admitted to intensive care

Description

Inclusion criteria for Patient:

  • Adult Patient
  • Estimated length of stay in intensive care exceeding 72 hours
  • No objection from the patient or the designated representative, if the patient is unable to consent to participate in the study

Inclusion criteria for Designated representative:

  • Adult Person
  • No objection to participate in the study

Inclusion criteria for Caregiver:

• No objection to participate in the study

Exclusion criteria :

  • Patients under legal protection (guardianship, conservatorship)
  • Pregnant or breastfeeding women
  • Disagreement among the patient's relatives regarding the designated representative.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Agreement rate
Time Frame: 48 hours
Assessment of the consistency between the priorities of patients and/or those assumed by the referring person and the priorities assumed by caregivers (resuscitation team and attending physician, if possible).
48 hours

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

University Hospital, Brest

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

February 15, 2026

Primary Completion (Estimated)

August 15, 2027

Study Completion (Estimated)

November 14, 2027

Study Registration Dates

First Submitted

February 11, 2026

First Submitted That Met QC Criteria

February 11, 2026

First Posted (Actual)

February 18, 2026

Study Record Updates

Last Update Posted (Actual)

March 5, 2026

Last Update Submitted That Met QC Criteria

March 3, 2026

Last Verified

January 1, 2026

More Information

Terms related to this study

Other Study ID Numbers

  • 29BRC25.0322
  • 2025-A02336-43 (Other Identifier: ANSM)

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

YES

IPD Plan Description

All collected data that underlie results in a publication

IPD Sharing Time Frame

Data will be available beginning five years and ending fifteen years following the final study report completion

IPD Sharing Access Criteria

Data access requests will be reviewed by the internal committee of Brest UH. Requestors will be required to sign and complete a data access agreement.

IPD Sharing Supporting Information Type

  • STUDY_PROTOCOL

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe